Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05416320
Other study ID # IRB00076702
Secondary ID
Status Withdrawn
Phase Early Phase 1
First received
Last updated
Start date August 2023
Est. completion date December 2023

Study information

Verified date August 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.


Description:

Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege through anti-inflammatory effects such as controlling Interferon gamma (IFN-γ) production. A recent study showed a significant decrease of vitamin D in Black patients with Central Centrifugal Cicatricial Alopecia (CCCA)"


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2023
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women who are eighteen years of age or older - biopsy-proven and/or clinical diagnosis of CCCA Stage II-IV - must be on stable treatment without changes for at least 3 months - Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology. Exclusion Criteria: - Males

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Calcipotriol
Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
Subject's already prescribed drug
Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.

Locations

Country Name City State
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Amount of hairline stabilization Standardized camera and dermatoscopic photographs Baseline
Primary Amount of hairline stabilization Standardized camera and dermatoscopic photographs Month 2
Primary Amount of hairline stabilization Standardized camera and dermatoscopic photographs Month 4
Primary Amount of hairline stabilization Standardized camera and dermatoscopic photographs Month 6
Secondary Amount of hair regrowth Standardized camera and dermatoscopic photographs Baseline, Month 2, Month 4, and Month 6
Secondary Signs and symptoms of disease score standardized questionnaire - higher scores denotes worse condition Month 2, Month 4, and Month 6
Secondary Dermatology Life Quality Index score scores of "not at all" to "very much" Baseline and Month 6
See also
  Status Clinical Trial Phase
Completed NCT03521687 - Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Phase 4
Not yet recruiting NCT05416333 - Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Early Phase 1
Recruiting NCT04764331 - A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia N/A
Recruiting NCT05759338 - A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia N/A
Completed NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia Early Phase 1
Completed NCT03044782 - Barriers to Care and QOL for CCCA Patients N/A
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A